Abbott’s Tendyne Receives CE Mark as the World’s First Transcatheter Mitral Valve Implantation System in Europe

 Abbott’s Tendyne Receives CE Mark as the World’s First Transcatheter Mitral Valve Implantation System in Europe

Abbott’s Tendyne Receives CE Mark as the World’s First Transcatheter Mitral Valve Implantation System in Europe

Shots:

  • Abbott’s Tendyne TMVI system received CE Mark to treat MR in patients requiring a heart valve replacement and is a safe and effective solution for patients who are not candidates for open-heart surgery or transcatheter mitral valve repair
  • The approval in the EU allows HCPs to completely treat MR and expands Abbott’s portfolio of innovative minimally invasive mitral valve solutions
  • Abbott’s Tendyne valve is a first-of-its-kind therapy to replace the mitral valve, without open surgery and when a transcatheter mitral repair is not possible. Tendyne valve provides relief from HF symptoms and improves QoL in high-surgical-risk patients

Click here to­ read full press release/ article | Ref: Abbott | Image: Star Tribune

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post